Pfizer (NYSE:PFE) Trading 0.4% Higher

Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price traded up 0.4% during mid-day trading on Tuesday . The stock traded as high as $25.83 and last traded at $25.74. 9,434,463 shares were traded during trading, a decline of 77% from the average session volume of 41,602,871 shares. The stock had previously closed at $25.64.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. TD Cowen lowered shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Argus lowered Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Finally, Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They set a "buy" rating and a $36.00 target price on the stock. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $36.33.

Pfizer Stock Down 0.1 %

The firm has a market capitalization of $145.02 billion, a PE ratio of 71.14, a P/E/G ratio of 1.14 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm's 50 day moving average price is $26.88 and its two-hundred day moving average price is $28.26.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company's revenue was down 41.3% on a year-over-year basis. During the same period last year, the firm earned $1.14 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.56%. The ex-dividend date is Thursday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 466.67%.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently modified their holdings of the company. Norges Bank acquired a new position in shares of Pfizer in the 4th quarter worth $2,129,927,000. Wellington Management Group LLP boosted its holdings in shares of Pfizer by 4.9% during the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company's stock worth $6,886,849,000 after purchasing an additional 11,099,024 shares during the period. Charles Schwab Investment Management Inc. grew its position in Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company's stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in Pfizer by 13.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company's stock worth $1,972,300,000 after buying an additional 8,298,920 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Pfizer by 30.9% during the 3rd quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company's stock valued at $797,901,000 after buying an additional 5,678,004 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.